RE:RE:PDT Potential Against Infection Sure does : )...here's a couple of interesting articles re: PDT potential against infection, including an endotracheal approach being investigated at Cedars Sinai Hospital.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7194064/
Aytu BioScience, Inc. has partnered with Cedars-Sinai to develop and commercialize its Healight Platform Technology, commonly known as “Healight”. The Healight technology delivers intermittent ultraviolet (UV) A light through an endotracheal catheter and according to the company, it is being studied as a potential treatment for coronavirus and other respiratory infections.
First developed in 2016 by the research team of the Medically Associated Science and Technology (MAST) Program at Cedars-Sinai and led by Mark Pimentel, MD, Healight has shown potential as an effective antiviral and antibacterial treatment. The device uses UVA light, because of all three forms of UV light, UVA has been shown to have the least amount of harm to mammalian cells while still killing viral and bacterial cells.
Aytu is working alongside a research team at Cedars-Sinai Hospital on an expedited regulatory process to try to use the technology faster for critically ill intubated patients. The company notes that along with being a potential treatment for viral and bacterial pathogens, Healight may also be helpful in treating bacterial infections in ventilator-associated pneumonia.
“Our team has shown that administering a specific spectrum of UV-A light can eradicate viruses in infected human cells (including coronavirus) and bacteria in the area while preserving healthy cells,” Dr. Pimentel of Cedars-Sinai stated.
Healight is not yet approved by the FDA for use or approved as a COVID-19 treatment, and more studies on its use in humans will be needed before it can be verified as effective. In addition to the UV light therapy, the company also recently acquired U.S. rights for a COVID-19 IgG/IgM Rapid Test, so it may soon have the ability to do rapid testing for the virus.